TechConnect Innovation Program

Microbiome Based Diagnostic for Inflammatory Bowel Disease

Biomecite Diagnostics, LLC, VA, United States

TECHNOLOGY SUMMARY

Biomecite Diagnostics is commercializing an Inflammatory Bowel Disease (IBD) diagnostic based on a microbiome signature technology developed at the University of Maryland, Baltimore. The technology uses a statistical, computational method to rapidly and comprehensively characterize and compare metagenomic data based on sequence composition.

Primary Application Area: Medical Devices

Technology Development Status: Prototype

Technology Readiness Level: TRL 3

FIGURES OF MERIT

Value Proposition: The diagnostic test for IBS and IBD will provide a non-invasive alternative or supplement to currently used endoscopy-based tests, particular in sensitive pediatric populations. The test will be less expensive and more accurate than existing solutions.

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Website: www.biomecite.com

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date: The team has received MII Phase 2 funding from TEDCO in Maryland

Primary Sources of Funding: Other

Looking for: Both Funding and Development Partners